Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 327 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Female Volunteers Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jun 26, 2026, 2:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

NCT05475821
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-990, Placebo for ABBV-990
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers

NCT02703181
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban (GSK557296), Placebo to match GSK557296
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jun 26, 2026, 2:33 PM EDT
Completed No phase listed Observational

Pelvic Pain in Women With Endometriosis

NCT00073801
View directory record Official record
Conditions
Endometriosis, Chronic Pelvic Pain
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 2:33 PM EDT
Not yet recruiting Phase 2 Interventional

Effects of Meal Macronutrients on Postprandial Lipids

NCT07313787
View directory record Official record
Conditions
Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer, Diabetes, Metabolic Associated Steatotic Liver Disease
Interventions
High carb then high fat breakfast, High fat then high carb breakfast
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers

NCT00467493
View directory record Official record
Conditions
Menstruation Disorders
Interventions
Anastrozole
Drug
Lead sponsor
Meditrina Pharmaceuticals
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Kalamazoo, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects

NCT01657890
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers, Safety and Tolerability in Elderly
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

NCT01403038
View directory record Official record
Conditions
Folliculogenesis
Interventions
elagolix
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
20
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323
View directory record Official record
Conditions
Renal Impairment
Interventions
LCQ908
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 26, 2026, 2:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Diet on Vascular Disease in Pre-Menopausal Women

NCT00484861
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Disease, Inflammation, Insulin, Triglycerides
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

NCT00417196
View directory record Official record
Conditions
Healthy
Interventions
QAX576
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2010 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants

NCT02802670
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-GDC-0810
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

NCT05891262
View directory record Official record
Conditions
Healthy Female Volunteers
Interventions
BMS-986196, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918614
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

NCT06476834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jun 26, 2026, 2:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Project to Examine the Effects of Exercise on Nocturnal Lipolysis in Men and Women

NCT02408510
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535
View directory record Official record
Conditions
Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers

NCT01132703
View directory record Official record
Conditions
Traumatic Brain Injury, Stroke
Interventions
Glyburide for Injection, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

NCT00291187
View directory record Official record
Conditions
Insomnia
Interventions
20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jun 26, 2026, 2:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 26, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

NCT01759576
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Jun 26, 2026, 2:33 PM EDT